ÂÜÀòÂÒÂ×

Frank has over 35 years of experience of toxicology and non-clinical drug development, gained in pharmaceutical (Senior Vice President, Sanofi), and contract research industries, and including 15 years as an independent consultant supporting the development of a diverse range of molecules. He has a comprehensive knowledge of non-clinical safety assessment including all aspects of regulatory guidance and advocacy, outsourced programme management, mechanistic toxicology and the application of new technologies to improve predictive screening.

He is a fellow of the British Toxicology Society, Past President of the Society and Visiting Professor in the Division of Integrative Systems Medicines at Imperial College, London. He has served as a Scientific Advisor for a number of technology and drug development SME’s and has Board level experience gained through various appointments including Executive Director, Stem Cells for Safer Medicines; Non-Executive Chairman, Maccine Pte, Singapore; Executive Director, Life Science Research Inc. etc.